DiaMedica Therapeutics
DMAC
92 hedge funds and large institutions have $96M invested in DiaMedica Therapeutics in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
94% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 18
41% more call options, than puts
Call options by funds: $314K | Put options by funds: $222K
18% more funds holding
Funds holding: 78 → 92 (+14)
16% more capital invested
Capital invested by funds: $82.8M → $96M (+$13.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.53% less ownership
Funds ownership: 24.68% → 23.15% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.67M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.13M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$775K |
| 4 |
MW
Members Wealth
Media,
Pennsylvania
|
+$758K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$684K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
-$9.35M |
| 2 |
Millennium Management
New York
|
-$3.13M |
| 3 |
Corient Private Wealth
Miami,
Florida
|
-$962K |
| 4 |
CI
Corient IA
Miami,
Florida
|
-$910K |
| 5 |
First Manhattan
New York
|
-$748K |
DMAC Hedge Fund Activity: Q4 2025 in Review
92 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2025, worth a combined $96M — up 16% from $82.8M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new DMAC positions and 8 closed out — a net gain of 14 holders — while 35 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $1.67M. The largest seller was Cooperman Leon G, cutting an estimated $9.35M.
- 92 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2025, up from 78 in Q3 2025.
- Funds reported $96M of DiaMedica Therapeutics stock for Q4 2025, up 16% quarter-over-quarter.
- 22 funds opened new DiaMedica Therapeutics positions in Q4 2025 and 8 closed out, a net change of +14 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2025 was BlackRock, an estimated $1.67M added.
- The largest DiaMedica Therapeutics seller in Q4 2025 was Cooperman Leon G, an estimated $9.35M sold.
Based on aggregated 13F filings for Q4 2025.